SynthesisWorld journal of urology2025
Minimally invasive treatments for benign prostatic hyperplasia in patients over 75: a systematic review.
Synthesis in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the efficacy and safety of minimally invasive surgical treatments (MISTs)—including Aquablation, Rezum, transperineal laser prostate ablation (TPLA), prostatic artery embolization (PAE), UroLift®, and the temporary implantable nitinol device (iTIND)—in patients aged 75 years and older with BPH.
methodsA systematic review was conducted in accordance with PRISMA 2020 guidelines and EAU standards. Literature searches were performed across PubMed, Scopus, and Web of Science up to July 15, 2025. Studies were included if they reported outcomes for male patients ≥ 75 years undergoing one of the specified MISTs, with a minimum of 50 patients per treatment group. Data extraction and risk of bias assessments were performed independently by two reviewers.
resultsOut of 830 initial records, 9 studies involving a total of 1099 patients met inclusion criteria. These included three PAE studies, four on Rezum, and two on UroLift. No eligible studies were found for Aquablation, iTIND, or TPLA. The mean patient age was 79.8 years, with baseline IPSS ranging from 15 to 27. MISTs were associated with significant symptom improvement and acceptable safety profiles. Adverse events were predominantly mild (Grade 1–2), with rates ranging from 10.0 to 39.2% across procedures. Serious complications (Grade ≥ 3) were rare, with an overall incidence of 1.2% for Rezum, 2.1% for PAE, and 2.5% for UroLift. PAE and Rezum demonstrated particularly favorable safety outcomes, with procedure times ranging from 6 to 115 min and variable catheterization durations. Most procedures were feasible under local anesthesia.
conclusionPAE, Rezum, and UroLift offer effective, less invasive alternatives to conventional surgery, demonstrating favorable safety and efficacy profiles in patients aged 75 and older. Each procedure, which can be performed under local or short-term anesthesia, offers lower perioperative morbidity and shorter hospital stays, providing practical treatment options for older men with multiple comorbidities.
Indexed as
Identifiers
41251804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.